Calcium oxalate crystal formation and growth (CaOx crystallization)

Calcium oxalate crystal formation and growth is the primary pathological process underlying the development of kidney stones, which affect a significant portion of the global population (StatPearls: Nephrolithiasis). This process is driven by the supersaturation of urine with calcium and oxalate ions, leading to a sequence of physicochemical events: nucleation, crystal growth, and aggregation (Khan et al., 2016). These crystals can cause cellular injury to the renal tubular epithelium and serve as a foundation for larger stone formation, often associated with Randall's plaques (PubMed: PMC4869510). Therapeutic strategies focus on disrupting this process by either reducing the availability of precursor ions—such as using Lumasiran to inhibit hepatic oxalate production—or by increasing the concentration of natural inhibitors like citrate that prevent crystal aggregation (FDA: Oxlumo; NIH: Kidney Stones). Managing this crystallization process is essential for preventing recurrent stone episodes and the progression to chronic kidney disease.

Other names

Calcium oxalate crystallizationCaOx nucleation and growthNephrolithiasis processUrolithiasis processCalcium oxalate biomineralization

Inhibition of crystal nucleation, growth, and aggregation by increasing urinary inhibitors or decreasing the concentration of stone-forming ions (calcium and oxalate).